ArticleFrontiers in oncology2022

Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment.

Michael Winkelmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.